The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
June 24th 2025
In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Korean Study Finds DOAC Use “Seems Effective” in Patients With MPNs
September 25th 2024A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.
Read More
Extended Time in ED Linked to Reported Racial Discrimination and Patient Dissatisfaction
September 24th 2024Boarding times in the emergency department (ED) have risen nationally, but the implications for health equity have remained understudied. This study investigated whether prolonged ED boarding contributed to perceived racial discrimination and dissatisfaction with care.
Read More
A Silent Risk: The Critical Role of Awareness and Early Detection in Familial Hypercholesterolemia
September 24th 2024September 24 celebrates Familial Hypercholesterolemia Awareness Day, which recognizes the importance of screening measures, education, and advocacy in a lesser-known, underdiagnosed cardiovascular condition.
Read More
FDA Approves First Self-Administered Nasal Spray Flu Vaccine
September 23rd 2024The FDA has approved FluMist (AstraZeneca) for self-administration by adults up to age 49 years or for caregiver administration for children aged 2 to 17 years, making it the first self-administered flu vaccine option.
Read More
Medicare High-Value Drug List Model Could Lower Out-of-Pocket Costs for 4 in 10 Beneficiaries
September 23rd 2024The proposed Medicare High-Value Drug List Model, also known as the Medicare $2 Drug List, could have modestly reduced out-of-pocket costs for 38% of beneficiaries if implemented in 2021.
Read More
New Research Unearths Evidence of Global Metabolic Disruption in Patients With SMA
September 21st 2024A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), adding to the literature on nutritional and metabolic complications linked to SMA.
Read More
Comorbidities Require Special Treatment Consideration for PAH
September 20th 2024In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses challenges to the optimal treatment of PAH, explained the researchers.
Read More
Type 2 Inflammatory Diseases and Impact on Quality of Life
September 18th 2024Panelists discuss how type 2 inflammatory diseases, such as asthma, atopic dermatitis, and chronic rhinosinusitis, can significantly impair patients’ quality of life through persistent symptoms and limitations in daily activities.
Watch
Meta-Study Analyzes Immunosuppressive Protocols for AAV Gene Therapy for Monogenic Disorders
September 18th 2024Immunosuppressants used in adeno-associated virus (AAV) gene therapy for monogenic disorders present an adverse effect profile that is consistent with high-dose steroid use in other conditions, according to a meta-study that analyzed immunosuppressive protocols.
Read More
Chronic Cough in Patients With ILD Linked to Reduced Quality of Life
September 18th 2024Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic cough in patients with idiopathic pulmonary fibrosis and other interstitial lung diseases.
Read More
Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions
September 18th 2024Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.
Watch
Fruquintinib in mCRC: Key Insights From FRESCO-2
September 18th 2024Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.
Watch
Dermatologist Dissects Rosacea Diagnosis Challenges Among Patients of Color
September 17th 2024Hilary Baldwin, MD, FAAD, highlighted diagnostic complexities and shared treatment strategies for rosacea in patients with darker skin tones at the Skin of Color Update in New York City last Friday.
Read More
OS Disparity, Driver Gene Variations by Race and Ethnicity Seen in CRC
September 17th 2024A substantial overall survival (OS) disparity by race and ethnicity was found in patients with colorectal cancer (CRC), with socioeconomic status and tumor molecular features largely contributing to the difference in OS.
Read More